Under China’s Amended Drug Law, Research and Development Institutions in China Now Permitted to Market Pharmaceuticals for the First Time
Qualified research institutions that develop their own pharmaceuticals will be eligible to hold marketing authorization permits in China under new legal guidance that went into effect in late September. Since 2015, when China first began implementing its Marketing Authorization Holder (MAH) system,... Read More